| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Basic Study |
| Article Title |
<Italic>Toxoplasma</Italic> ROP16I/III ameliorated inflammatory bowel diseases via inducing M2 phenotype of macrophages
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yong-Wei Xu, Rui-Xin Xing, Wen-Hui Zhang, Lu Li, Yi Wu, Jing Hu, Cong Wang, Qing-Li Luo, Ji-Long Shen and Xi Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81471983 |
| Key Research and Development Plan Project of Anhui Province, Department of Science and Technology 2019 |
201904a07020043 |
| Key Project of Natural Science Research in the Universities of Anhui Provence |
KJ2017A202 |
| Research Fund Project of Anhui Institute of Transforming Medicine |
2017zhyx04 |
|
| Corresponding Author |
Xi Chen, MD, PhD, Chief Doctor, Dean, Director, Director, Doctor, Doctor, Instructor, Professor, Senior Researcher, Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, Anhui Province, China., Hefei 230022, Anhui Province, China. ayfychenxi@163.com |
| Key Words |
Toxoplasma ROP16Ⅰ/Ⅲ; Caco-2; Inflammatory bowel disease; Immunity; Classically activated macrophages; Alternatively activated macrophages |
| Core Tip |
Toxoplasma ROP16Ⅰ/Ⅲ (ToxoROP16Ⅰ/Ⅲ) induced RAW264.7 polarization to M2 macrophage, down-regulation the M1 associated inflammation response and protective Caco-2 intestinal epithelial cells. ToxoROP16Ⅰ/Ⅲ can phosphorylate and activate the transcription factors signal transducer and activator of signal transducer and activator of transcription (Stat) 3 and Stat6, promote the polarization of M2 cells, enhance the synthesis of arginase-1, interleukin (IL)-10, transforming growth factor-β1, and IL-13. M2 mixed with M1 macrophage cells, down-regulation the proinflammatory factors IL-1β, tumour necrosis factor-α, IL-6, nitric oxide (NO), and inducible NO synthase. Then co-culture with Caco-2 cells through transwell, alleviated Caco-2 cell apoptosis and caspase-3, -8, and -9 associated proteins. So this study aims to identify that ToxoROP16Ⅰ/Ⅲ may provide a novel strategy for IBD immunotherapy with parasite-derived effector molecules. |
| Publish Date |
2019-12-06 08:06 |
| Citation |
Xu YW, Xing RX, Zhang WH, Li L, Wu Y, Hu J, Wang C, Luo QL, Shen JL, Chen X. Toxoplasma ROP16I/III ameliorated inflammatory bowel diseases via inducing M2 phenotype of macrophages. World J Gastroenterol 2019; 25(45): 6634-6652 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i45/6634.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i45.6634 |
